Regulatory expectations for virus inactivation validation in vaccine downstream processes Regulatory expectations for virus inactivation validation in vaccine downstream processes Viral clearance is a critical aspect of ensuring the safety of biological products, particularly vaccines. As the vaccine landscape continues to evolve, regulatory affairs professionals must navigate complex guidelines pertaining to virus inactivation and viral filtration validation. This article discusses the current regulations, guidelines, and expectations surrounding virus inactivation validation in downstream processes for vaccine production across the US, EU, and UK, providing regulatory professionals with a comprehensive guide. Context The necessity for viral inactivation validation arises from the imperative…

Optimizing hold times and conditions for effective virus inactivation with strong validation data Optimizing hold times and conditions for effective virus inactivation with strong validation data Regulatory Affairs Context In the pharmaceutical and biotechnology sectors, ensuring the safety and efficacy of biological products is paramount. Viral clearance and biological safety validation form a critical component of this effort. Regulatory agencies such as the FDA, EMA, and MHRA emphasize the importance of demonstrating that viral inactivation methods are robust and reproducible. This article provides a comprehensive manual on viral filtration validation, focusing on optimizing hold times and conditions. Legal/Regulatory Basis The…